← Back to Search

Abatacept with Oral Immunotherapy for Peanut Allergy (ATARI Trial)

Phase 2

Waitlist Available

Research Sponsored by Philippe Bégin

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Male or female subjects 14 to 50 years old at screening visit

Be younger than 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up weeks 2, 6, 12, 36 and 48

Awards & highlights

ATARI Trial Summary

This trial will test if the drug abatacept can help people with severe peanut allergies achieve remission.

Who is the study for?

This trial is for 14 to 50-year-olds with a severe, persistent peanut allergy confirmed by specific tests. Participants must be willing to follow the study's rules but can't join if they've had bad reactions to abatacept, are at risk of infections like HIV, have uncontrolled asthma or heart issues, use certain medications like steroids or antidepressants, are pregnant/breastfeeding, or have other chronic diseases that could interfere.Check my eligibility

What is being tested?

The trial is testing whether adding Abatacept to peanut oral immunotherapy helps adolescents and adults with severe peanut allergies reach remission. It's a phase 2a study where half the participants get Abatacept and the other half get a placebo for six months while undergoing immunotherapy.See study design

What are the potential side effects?

Possible side effects of Abatacept may include increased risk of infections due to immune system suppression, infusion-related reactions such as discomfort or pain at injection site, headache, nausea and potential allergic responses.

ATARI Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 14 and 50 years old.

ATARI Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ weeks 2, 6, 12, 36 and 48

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~weeks 2, 6, 12, 36 and 48

This trial's timeline: 3 weeks for screening, Varies for treatment, and weeks 2, 6, 12, 36 and 48 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Peanut specific/total IgE at week 24

Secondary outcome measures

Adverse events

Desensitization

Desensitization speed

+4 more

Other outcome measures

Atopy patch test

Peanut specific/total IgE, other time points

Peanut-specific IgG4, other time points

+2 more

Side effects data

From 2017 Phase 2 trial • 37 Patients • NCT00932828

78%

Rash (not hives)

62%

Nausea/vomiting

59%

Abdominal pain

54%

Hives

51%

Skin/oral pruritus

35%

Sneezing/congestion

30%

Multiple symptoms

100%

80%

60%

40%

20%

Study treatment Arm

Peanut Oral Immunotherapy

ATARI Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: AbataceptExperimental Treatment2 Interventions

Group II: PlaceboPlacebo Group2 Interventions

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Abatacept

2005

Completed Phase 4

~112150

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Philippe BéginLead Sponsor

2 Previous Clinical Trials

588 Total Patients Enrolled

Centre hospitalier de l'Université de Montréal (CHUM)OTHER

366 Previous Clinical Trials

129,623 Total Patients Enrolled

Media Library

Peanut Allergy Research Study Groups: Abatacept, Placebo

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still vacancies within this experiment for participants?

"Affirmative. Per the information hosted on clinicaltrials.gov, this experiment is actively engaged in recruiting individuals for participation. It was originally posted to the website on March 1st 2022 and updated as recently as May 3rd 2022; it requires 14 participants from one location."

Answered by AI

In what contexts is Peanut oral immunotherapy typically administered?

"Peanut oral immunotherapy is a popular treatment for rheumatoid arthritis, but it can also reduce symptoms of psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and severe juvenile idiopathic arthritis."

Answered by AI

Are there any other experiments that have been conducted using Peanut oral immunotherapy?

"Currently, 8 of the 34 studies researching Peanut oral immunotherapy have reached Phase 3. These trials are spread across 771 locations with a significant concentration in Toronto, Ontario."

Answered by AI

What is the aggregate figure of participants involved in this research?

"Affirmative, the details on clinicaltrials.gov verify that this medical experiment is recruiting participants now. This research was initially posted on March 1st 2022 and most recently modified on May 3rd 2022. The study requires 14 individuals to be admitted at a single site for testing purposes."

Answered by AI

Who is entitled to partake in this research study?

"To partake in this medical trial, applicants must be 14 to 50 years old and possess a documented peanut allergy. The current recruitment drive is looking for approximately fourteen volunteers."

Answered by AI

Does this research endeavor accept individuals aged 30 or older?

"To be eligible for this research, individuals must be between the ages of 14 and 50. 95 studies are available for minors and 185 trials are open to participants aged 65 or older."

Answered by AI

Is Peanut oral immunotherapy a secure procedure for individuals?

"Although clinical data suggesting efficiency is absent, prior research has established enough evidence to assess the safety of Peanut oral immunotherapy at a score of 2."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Adjuvant Treatment With Abatacept to Promote Remission During Peanut Oral Immunotherapy

Philippe Bégin 2022. "Adjuvant Treatment With Abatacept to Promote Remission During Peanut Oral Immunotherapy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04872218.

All > Penicillin Allergy > Peanut Allergy